Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
222 Clinical Trials near Greenfield, IN
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerRadiation Therapy + Olaparib for Breast Cancer
Fishers, Indiana
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Uncontrolled Infection, Heart Failure, Others
Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers
300 Participants Needed
Maintenance Chemotherapy for Lung Cancer
Indianapolis, Indiana
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation therapy such as radiation/stereotactic body radiation or surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy and local consolidation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Untreated Brain Metastases, Prior Invasive Malignancy, Others
Must Be Taking:Immunotherapy, Platinum-based Chemotherapy
218 Participants Needed
Venetoclax + Carfilzomib + Dexamethasone for Multiple Myeloma
Indianapolis, Indiana
This trial is testing a combination of three drugs to treat patients with multiple myeloma whose cancer has come back or didn't respond to previous treatments. The drugs work together to kill cancer cells and help manage side effects. The study aims to find out if this combination is safe and effective. Filanesib, one of the drugs in the trial, has shown durable activity in patients with multiple myeloma in previous studies.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Active Infections, Diabetes, Others
120 Participants Needed
Pemetrexed + Cisplatin +/- Cediranib for Mesothelioma
Beech Grove, Indiana
This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed disodium and cisplatin together with cediranib maleate may kill more tumor cells.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:HIV, Pregnancy, Heart Failure, Others
Must Not Be Taking:Proarrhythmic Drugs
117 Participants Needed
Vorinostat + Rituximab + Chemotherapy for Diffuse Large B-Cell Lymphoma
Beech Grove, Indiana
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab and combination chemotherapy and to see how well it works in treating patients with newly diagnosed stage II, stage III, or stage IV diffuse large B-cell lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cell-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving vorinostat together with rituximab and combination chemotherapy may kill more cancer cells.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:HIV, Pregnancy, Prior Chemotherapy, Others
Must Not Be Taking:Valproic Acid, Torsades De Pointes Risk
83 Participants Needed
Dinaciclib for Advanced Melanoma
Beech Grove, Indiana
This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Ocular Melanoma, Others
Must Not Be Taking:CYP3A4 Inhibitors, Inducers
72 Participants Needed
Chemotherapy for Breast Cancer
Beech Grove, Indiana
This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Heart Failure, Hypertension, Others
454 Participants Needed
Chemotherapy + Stem Cell Transplant for Acute Lymphoblastic Leukemia
Beech Grove, Indiana
This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 60
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, HIV, Others
Must Be Taking:Tyrosine Kinase Inhibitors
97 Participants Needed
Azacitidine + Gemtuzumab for Acute Myeloid Leukemia
Beech Grove, Indiana
This phase II trial is studying the side effects of giving azacitidine together with gemtuzumab ozogamicin to see how well it works in treating older patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Azacitidine may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving azacitidine together with gemtuzumab ozogamicin may kill more cancer cells.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:60+
Key Eligibility Criteria
Disqualifiers:CNS Involvement, Prior Malignancy, Others
Must Not Be Taking:Azacitidine, Gemtuzumab Ozogamicin
133 Participants Needed
Imatinib or Dasatinib for Chronic Myeloid Leukemia
Beech Grove, Indiana
This randomized phase IIB trial studies imatinib mesylate at two different doses and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia. Imatinib mesylate or dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Major Surgery, Cardiac Symptoms, Others
406 Participants Needed
TNB-383B for Multiple Myeloma
Indianapolis, Indiana
This trial is testing TNB-383B, a special antibody, in patients with hard-to-treat multiple myeloma. The treatment helps immune cells find and destroy cancer cells. It aims to offer a new option for patients who have not responded to multiple previous treatments.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Other Malignancy, CNS Involvement, Others
Must Be Taking:Proteasome Inhibitors, Immunomodulatory Imides, Anti-CD38 Antibodies
220 Participants Needed
Vodobatinib for Chronic Myeloid Leukemia
Indianapolis, Indiana
Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:T315I, HIV, Hepatitis B, Others
Must Be Taking:TKIs
122 Participants Needed
Serabelisib + Diet/Nab-paclitaxel for Solid Cancers
Indianapolis, Indiana
This trial is testing a new cancer drug called serabelisib with a special diet that lowers insulin levels, and sometimes with another drug called nab-paclitaxel. nab-Paclitaxel is used for treating triple-negative breast cancer. It targets cancer patients who suffer from severe side effects of current treatments. The goal is to block cancer growth pathways and lower insulin to reduce side effects and improve treatment effectiveness.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Brain Tumor, Diabetes, Cardiac Disease, Others
Must Not Be Taking:PI3K Inhibitors, Insulin, Antacids, Others
68 Participants Needed
SGN-B7H4V for Advanced Cancers
Indianapolis, Indiana
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Other Malignancy, CNS Metastases, Others
Must Not Be Taking:Corticosteroids, MMAE Agents
236 Participants Needed
PBCAR0191 for Blood Cancer
Indianapolis, Indiana
This trial tests a new therapy using specially altered immune cells in adults with certain types of blood cancers that have not responded to other treatments. The goal is to find a safe and effective amount.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:CNS Disease, Cardiovascular Disease, Others
Must Not Be Taking:Antivirals, Immunosuppressants
129 Participants Needed
Ruxolitinib Cream for Prurigo
Indianapolis, Indiana
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Chronic Pruritus, Active AD Lesions, HBV, HCV, Others
23 Participants Needed
RLY-5836 for Advanced Breast Cancer
Indianapolis, Indiana
This trial is testing a new drug called RLY-5836 in patients with advanced cancers that have a PIK3CA mutation. The drug aims to block this mutation to slow down tumor growth. The study will determine how safe and effective the drug is.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Diabetes, Others
Must Be Taking:GnRH Agonists
265 Participants Needed
RLY-2608 + Fulvestrant for Breast Cancer
Indianapolis, Indiana
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4/6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients with HR+ HER2- locally advanced or metastatic breast cancer. The RLY-2608 single agent arm, RLY-2608 + fulvestrant combination arm, and triple combination arms will have 2 parts: a dose escalation (Part 1) and a dose expansion (Part 2).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Diabetes, Cardiovascular Disease, CNS Metastases, Others
Must Be Taking:GnRH Agonist
930 Participants Needed
XL092 + Immuno-Oncology Agents for Solid Tumors
Indianapolis, Indiana
This trial is testing a new drug called XL092 alone and with other cancer drugs in patients with advanced solid tumors. The goal is to see if these treatments can safely stop or slow tumor growth and help the immune system fight cancer more effectively.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Uncontrolled Illness, Pregnancy, Others
Must Not Be Taking:Anticoagulants, Complementary Medicines
1274 Participants Needed
ABBV-400 for Advanced Solid Cancers
Indianapolis, Indiana
This trial tests a new drug called ABBV-400 for adults with advanced cancers. The study aims to find the best dose and see how well it works, both alone and with other treatments. Patients will receive the drug through an IV and be closely monitored for effects and side effects.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Interstitial Lung Disease, Pneumonitis, Others
520 Participants Needed
Why Other Patients Applied
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
LOXO-338 for Blood Cancers
Indianapolis, Indiana
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:CNS Involvement, HIV, Hepatitis B/C, Others
Must Not Be Taking:CYP3A4 Inhibitors, Antifungals, P-gp Inhibitors, Others
316 Participants Needed
ABBV-514 + Budigalimab for Lung & Head and Neck Cancers
Indianapolis, Indiana
This trial is testing two experimental drugs, ABBV-514 and Budigalimab, on adults with specific types of cancer. The goal is to find out if these drugs can help treat lung and head/neck cancers by monitoring their effects and side effects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:EGFR Mutations, ALK Rearrangements, Others
512 Participants Needed
Amivantamab SC for Cancer
Indianapolis, Indiana
The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Uncontrolled Illness, Brain Metastases, Others
Must Be Taking:Anti-EGFR TKI
158 Participants Needed
LY3484356 for Breast Cancer
Indianapolis, Indiana
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Infections, CNS Cancer, Others
Must Not Be Taking:Everolimus, Alpelisib
500 Participants Needed
Cervical Myelopathy for Hip Fracture
Fishers, Indiana
Recent evidence has demonstrated a high rate of undiagnosed cervical myelopathy in patients presenting with hip fractures from a ground level fall. Identification and treatment of cervical myelopathy can help prevent falls and future fragility fractures. The purpose of this study is to screen ground level fall hip fracture patients for cervical myelopathy using a history, physical exam, and then offer an MRI if indicated.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 100
Key Eligibility Criteria
Disqualifiers:Dementia, Parkinson's, Stroke, Others
75 Participants Needed
Integrity Implant System for Rotator Cuff Tears
Fishers, Indiana
The study design is a prospective, multi-center, single-arm, non-randomized post market clinical follow-up study to confirm the performance, safety and clinical benefit of the Integrity Implant System when used for rotator cuff tear augmentation (with or without repair).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Pregnancy, Type I Diabetes, Smoking, Others
Must Not Be Taking:Immunosuppressants, Oral Steroids
150 Participants Needed
Reducing Fall Prevention Alarms in Hospitals
Indianapolis, Indiana
This is a Hybrid II de-implementation study to reduce use of fall prevention alarms in hospitals. The intervention consists of tailored, site-specific approaches for three core implementation strategies: education, audit/feedback and opinion leaders. Hospital units will be randomized to low-intensity or high-intensity coaching for the implementation of the tailored strategies.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
300 Participants Needed
MSCopilot® App for Multiple Sclerosis
Indianapolis, Indiana
This trial is testing MSCopilot® Detect, a smartphone app that helps people with Multiple Sclerosis (MS) monitor their condition from home. The app aims to make it easier to track disease progression and improve patient care. It involves 314 MS patients from several countries who will use the app to complete periodic questionnaires and tests. MSCopilot is a software medical device designed for the self-assessment of people with Multiple Sclerosis (PwMS), validated against traditional tests.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:30 - 65
Key Eligibility Criteria
Disqualifiers:Medically Unstable, Visual Acuity, Pregnancy, Others
336 Participants Needed
ECM Valve Replacement for Tricuspid Valve Disease
Indianapolis, Indiana
The goal of this pivotal study is to demonstrate the safety and performance of the Cor TRICUSPID ECM (extracellular matrix) Valve (or Cor PEDIATRIC Tricuspid ECM Valve) for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric patients. The main question(s) it aims to answer are:
* whether the device may be implanted successfully and safely, and
* whether the device effectively treats tricuspid valve disease and dysfunction through 12 months
Participants will undergo:
* preoperative evaluation
* tricuspid valve replacement with the Cor TRICUSPID ECM Valve
* postoperative evaluation, including at hospital discharge, 30 days, 6 months, and 12 months, and then annually thereafter through 5 years
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Small Tricuspid Annulus, Low LVEF, High Pulmonary Pressure, Emergency Cardiac Procedure, Cardiac Transplant, Others
Must Not Be Taking:Bone Marrow Suppressants
92 Participants Needed
Left Atrial Appendage Exclusion for Stroke Prevention
Indianapolis, Indiana
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Atrial Fibrillation, Heart Transplant, Infection, Others
6573 Participants Needed
Know someone looking for new options?
Spread the word